Eli Lilly (LLY): Discounted on DCF but Full of Optimism
Despite a 406.3% return over five years, Eli Lilly (LLY) appears undervalued on a DCF basis. However, such massive gains often mean optimism is already reflected in the price, putting focus on what investors are paying for future growth.
Key Numbers
A recent analysis of Eli Lilly (LLY) reveals an interesting paradox: while the stock has delivered a cumulative return of 406.3% over the past five years, estimates of intrinsic value using the Discounted Cash Flow (DCF) model suggest the stock still trades at a discount to its fair value.
Fair Value vs. Market Price
According to the DCF model, the stock's intrinsic value is estimated above its current price, indicating a margin of safety. However, the question is whether this discount is real or a result of overly optimistic assumptions in the model.
What Does the 406% Return Mean?
The massive five-year return (more than 5x) typically reflects strong growth expectations that are already priced into the stock. This means investors are now paying a high price for future growth, reducing the likelihood of similar returns going forward.
The Role of Obesity Drugs
Much of the optimism around Eli Lilly stems from the success of its obesity drugs like Mounjaro and Zepbound. These drugs have opened a huge new market for the company, but they also raise the bar for expectations.
What This Means for Investors
The analysis does not recommend buying or selling the stock, but it highlights the importance of balancing value indicators (DCF discount) with momentum indicators (high historical return). Investors are encouraged to examine the model's assumptions and assess whether future growth expectations are realistic.
Frequently Asked Questions
Found this useful? Share it